1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Switzerland >
  5. Kuur Therapeutics Acquires Delenex Therapeutics AG

M&A Deal Summary

Kuur Therapeutics Acquires Delenex Therapeutics AG

On July 12, 2016, Kuur Therapeutics acquired life science company Delenex Therapeutics AG

Acquisition Highlights
  • This is Kuur Therapeutics’ 1st transaction in the Life Science sector.
  • This is Kuur Therapeutics’ 1st transaction in Switzerland.

M&A Deal Summary
Date 2016-07-12
Target Delenex Therapeutics AG
Sector Life Science
Buyer(s) Kuur Therapeutics
Deal Type Add-on Acquisition

Target

Delenex Therapeutics AG

Schlieren, Switzerland
Delenex Therapeutics AG is a clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Kuur Therapeutics

London, United Kingdom
Category Company
Sector Life Science
DESCRIPTION

Kuur Therapeutics is a developer, manufacturer, and marketer of cellular immunotherapy products for the treatment of cancer and infections. Kuur Therapeutics’s lead oncology product, baltaleucel-T, is aimed at a range of cancers associated with the oncogenic Epstein Barr virus (EBV), including non-Hodgkin lymphomas, Hodgkin lymphoma, and nasopharyngeal carcinoma. Kuur Therapeutics is based in London, United Kingdom.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Switzerland M&A 1 of 1
Year: 2016 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal